Evidence map›Paper›PMID 24362548›Full record

ReviewClinical reviews in allergy & immunology2014

Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review.

Yoshimasa Saito, Hidetsugu Saito, Gangning Liang, Jeffrey M Friedman

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Revolutionizing bone tumor management: cutting-edge breakthroughs in limb-saving treatments.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. 2021 update on thyroid-associated ophthalmopathy.Journal of endocrinological investigation · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Two-layer regulation ofAmerican journal of translational research · 2020
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Yoshimasa SaitoDivision of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan, yoshimasa.saito@gmail.com.
Hidetsugu Saito
Gangning Liang
Jeffrey M Friedman
Keio University · JPUniversity of Southern California · USVanderbilt University Medical Center · US

Funding

Determining the mechanistic and therapeutic roles of microRNAs in bladder cancerR01CA138794 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIANG, GANGNING · 2010 to 2013
$1.0M
NCI NIH HHS R01 CA138794
6 · The paper itself

Abstract

Epigenetic markers such as DNA methylation and histone modifications around promoter regions modify chromatin structure and regulate expression of downstream genes. In fact, aberrant epigenetic modifications are common events in human disease including tumorigenesis and autoimmunity. Small non-coding RNAs named microRNAs (miRNAs) are modulators of gene expression and play critical roles in various cellular processes. Several miRNAs have been characterized as tumor suppressors or oncogenes in cancer, and recent reports implicate certain miRNAs in the pathogenesis of autoimmune diseases. Epigenetic investigations have shown that distinct miRNAs are directly regulated by DNA methylation and histone modifications at their promoters. Moreover, miRNAs themselves are key participants in regulating the chromatin modifying machinery. Chromatin-modifying drugs such as DNA methylation inhibitors and histone deacetylase inhibitors have shown efficacy in human malignancies and there is some evidence that these drugs may be useful in autoimmune disease. The benefits of these drugs are at least partially mediated by restoring expression of epigenetically silenced tumor suppressor genes, including miRNAs. The complex layers regulating gene expression have yet to be fully elucidated, but it is clear that epigenetic alterations and miRNA misexpression are essential events in pathologic processes, especially cancer and autoimmune disease, and represent promising therapeutic targets.

Indexed as

Autoimmune DiseasesAutoimmunityChromatinDNA MethylationEpigenesis, GeneticHistone Deacetylase InhibitorsHistonesHumansImmunologic FactorsMicroRNAsNeoplasmsPromoter Regions, GeneticTumor Suppressor ProteinsChromatinHistone Deacetylase InhibitorsHistonesImmunologic FactorsMicroRNAsTumor Suppressor Proteins

Identifiers

PMID24362548
PMCPMC4651002
OpenAlexW1993967927

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.